ERBB2 and neoplasm: Previous studies have shown that 89Zr-trastuzumab supports clinical decision making when HER2 status could not be determined by standard procedures (bone scan, 18F-FDG PET, CT and biopsy) and is able to determine tumor heterogeneity (NCT01832051, NCT01565200) [95,96].